Xofigo 1,100 KBQ/ML vials
Ended Awarded Last action
- Contract number
- SPE2DR26FMEB2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,944
Award facts
- Contract value 100% obligated
- $13,944.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,944.42 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOFIGO 1,100 KBQ/ML vials. The delivery order, issued on December 8, 2025, with an ultimate completion date of December 30, 2025, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. XOFIGO is a radiopharmaceutical used in oncology treatment, reflecting DMS Pharmaceutical Group's established role as a specialized supplier of cancer therapeutics and other critical pharmaceutical products to Department of Defense medical facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, awarded November 13, 2025, with a $499,999,999 ceiling value through December 31, 2036. The PPV-G GEN V represents a broader $30.3 billion acquisition strategy designed to provide the Department of Defense with a comprehensive supply of branded and generic prescription medications, biologics, over-the-counter drugs, and medical consumables to support military healthcare operations worldwide. DMS Pharmaceutical Group's performance on numerous delivery orders demonstrates its capability as a critical pharmaceutical supplier within the federal military medical supply chain, with no subcontractors identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FMEB2?
SPE2DR26FMEB2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FMEB2 worth?
The government has obligated $13,944 on SPE2DR26FMEB2.
Is contract SPE2DR26FMEB2 an order under another contract?
Yes. SPE2DR26FMEB2 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEB2 competed?
The extent of competition for SPE2DR26FMEB2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award